
Matthias J. MÃ¹/₄ller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6021462/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Circadian preference and sleep quality in healthy controls and psychiatric inpatients with major depressive disorder – An actigraphy study incorporating morning and evening mood assessments. Chronobiology International, 2022, 39, 249-260.	2.0	1
2	Preventing COVID-19 outbreaks through surveillance testing in healthcare facilities: a modelling study. BMC Infectious Diseases, 2022, 22, 105.	2.9	13
3	Influence of chronotype on daily mood fluctuations: pilot study in patients with depression. BJPsych Open, 2020, 6, e17.	0.7	9
4	Evening preference and poor sleep independently affect attentional-executive functions in patients with depression. Psychiatry Research, 2019, 281, 112533.	3.3	12
5	Prescription of Benzodiazepines and Related Drugs in Patients with Mild Cognitive Deficits and Alzheimer's Disease. Pharmacopsychiatry, 2019, 52, 84-91.	3.3	10
6	Perceived Discrimination in Patients With Psychiatric Disorder and Turkish Migration Background in Germany. Journal of Nervous and Mental Disease, 2016, 204, 542-546.	1.0	5
7	Dysconnectivity of the inferior frontal gyrus: Implications for an impaired self-other distinction in patients with schizophrenia. Psychiatry Research - Neuroimaging, 2014, 223, 202-209.	1.8	28
8	The "DGPPN-Cohortâ€: a national collaboration initiative by the German Association for Psychiatry and Psychotherapy (DGPPN) for establishing a large-scale cohort of psychiatric patients. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 695-701.	3.2	17
9	Study protocol of the Diabetes and Depression Study (DAD): a multi-center randomized controlled trial to compare the efficacy of a diabetes-specific cognitive behavioral group therapy versus sertraline in patients with major depression and poorly controlled diabetes mellitus. BMC Psychiatry, 2013. 13. 206.	2.6	18
10	Hyperintentionality during automatic perception of naturalistic cooperative behavior in patients with schizophrenia. Social Neuroscience, 2013, 8, 489-504.	1.3	28
11	Potential Cost-effectiveness of Therapeutic Drug Monitoring for Depressed Patients Treated With Citalopram. Therapeutic Drug Monitoring, 2013, 35, 396-401.	2.0	29
12	Relapse (Number of Detoxifications) in Abstinent Male Alcohol-Dependent Patients as Related to Personality Traits and Types of Tolerance to Frustration. Neuropsychobiology, 2013, 67, 241-248.	1.9	22
13	Depressive Attribution Style and Stressor Uncontrollability Increase Perceived Pain Intensity after Electrical Skin Stimuli in Healthy Young Men. Pain Research and Management, 2013, 18, 203-206.	1.8	4
14	Stage-Dependent Agreement between Cerebrospinal Fluid Proteins and FDG-PET Findings in Alzheimer's Disease. Current Alzheimer Research, 2012, 9, 241-247.	1.4	16
15	Will it hurt less if I believe I can control it? Influence of actual and perceived control on perceived pain intensity in healthy male individuals: a randomized controlled study. Journal of Behavioral Medicine, 2012, 35, 529-537.	2.1	28
16	Hippocampal atrophy as a surrogate of neuronal involvement in Fabry disease. Journal of Inherited Metabolic Disease, 2012, 35, 363-367.	3.6	25
17	Association Between Citalopram Serum Levels and Clinical Improvement of Patients With Major Depression. Journal of Clinical Psychopharmacology, 2011, 31, 281-286.	1.4	33
18	Cost and Care of Patients with Alzheimer's Disease: Clinical Predictors in German Health Care Settings, Journal of Alzheimer's Disease, 2011, 27, 723-736.	2.6	48

#	Article	IF	CITATIONS
19	Relationships between hippocampal microstructure, metabolism, and function in early Alzheimer's disease. Brain Structure and Function, 2011, 216, 219-226.	2.3	19
20	Functional implications of hippocampal degeneration in early Alzheimer's disease: a combined DTI and PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2219-2227.	6.4	38
21	Helplessness and perceived pain intensity: relations to cortisol concentrations after electrocutaneous stimulation in healthy young men. BioPsychoSocial Medicine, 2011, 5, 8.	2.1	30
22	Clinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with Schizophrenia. Schizophrenia Research and Treatment, 2011, 2011, 1-7.	1.5	0
23	Increased hippocampal head diffusivity predicts impaired episodic memory performance in early Alzheimer's disease. Neuropsychologia, 2010, 48, 1447-1453.	1.6	29
24	Cognitive behavioural therapy in elderly type 2 diabetes patients with minor depression or mild major depression: study protocol of a randomized controlled trial (MIND-DIA). BMC Geriatrics, 2010, 10, 21.	2.7	15
25	Cerebrospinal Fluid Tau Protein Levels and ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography in the Differential Diagnosis of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2010, 30, 245-253.	1.5	8
26	Can delusions be self-assessed? Concordance between self- and observer-rated delusions in schizophrenia. Psychiatry Research, 2010, 178, 249-254.	3.3	70
27	Implicit attributional style revisited: Evidence for a state-specific "self-decreasing―implicit attributional style in patients with persecutory delusions. Cognitive Neuropsychiatry, 2010, 15, 451-476.	1.3	11
28	CSF APPsα and Phosphorylated Tau Protein Levels in Mild Cognitive Impairment and Dementia of Alzheimer's Type. Journal of Geriatric Psychiatry and Neurology, 2009, 22, 3-9.	2.3	28
29	Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. Journal of Psychopharmacology, 2009, 23, 278-286.	4.0	23
30	Cost-effectiveness analysis of cognitive behaviour therapy for treatment of minor or mild-major depression in elderly patients with type 2 diabetes: study protocol for the economic evaluation alongside the MIND-DIA randomized controlled trial (MIND-DIA CEA). BMC Geriatrics, 2009, 9, 25.	2.7	9
31	Late structural alterations of cerebral white matter in longâ€ŧerm survivors of childhood leukemia. Journal of Magnetic Resonance Imaging, 2008, 27, 1250-1255.	3.4	48
32	Functional relevant loss of long association fibre tracts integrity in early Alzheimer's disease. Neuropsychologia, 2008, 46, 1698-1706.	1.6	90
33	Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World Journal of Biological Psychiatry, 2008, 9, 212-218.	2.6	97
34	Gender-specific associations of depression with positive and negative symptoms in acute schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1095-1100.	4.8	21
35	A monoamine oxidase B gene variant and short-term antidepressant treatment response. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1370-1377.	4.8	22
36	Diagnostic utility of hippocampal size and mean diffusivity in amnestic MCI. Neurobiology of Aging, 2007, 28, 398-403.	3.1	130

Matthias J. Müller

#	Article	IF	CITATIONS
37	Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World Journal of Biological Psychiatry, 2007, 8, 123-126.	2.6	49
38	TheMAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 325-331.	1.7	57
39	Quantification of brain tissue alterations in Fabry disease using diffusionâ€ŧensor imaging. Acta Paediatrica, International Journal of Paediatrics, 2007, 96, 33-36.	1.5	20
40	FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research - Neuroimaging, 2007, 155, 167-171.	1.8	48
41	Therapeutic drug monitoring for optimizing amisulpride therapy in patients with Schizophrenia. Journal of Psychiatric Research, 2007, 41, 673-679.	3.1	51
42	Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. NeuroImage, 2006, 30, 1332-1339.	4.2	71
43	Detection of Depression in Acute Schizophrenia: Sensitivity and Specificity of 2 Standard Observer Rating Scales. Canadian Journal of Psychiatry, 2006, 51, 387-392.	1.9	31
44	Recurrent brief depression in a female patient with Fabry disease. Bipolar Disorders, 2006, 8, 418-419.	1.9	7
45	Pattern of microstructural brain tissue alterations in Fabry disease. Journal of Neurology, 2006, 253, 780-787.	3.6	46
46	CNS manifestations of Fabry's disease. Lancet Neurology, The, 2006, 5, 791-795.	10.2	172
47	Predicting conversion to dementia in mild cognitive impairment by volumetric and diffusivity measurements of the hippocampus. Psychiatry Research - Neuroimaging, 2006, 146, 283-287.	1.8	113
48	Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology, 2006, 31, 256-264.	2.7	68
49	The Calgary Depression Rating Scale for schizophrenia in a healthy control group: Psychometric properties and reference values. Journal of Affective Disorders, 2005, 88, 69-74.	4.1	30
50	SEQUENTIALLY ADJUSTED RANDOMIZATION TO FORCE BALANCE IN CONTROLLED TRIALS WITH UNKNOWN PREVALENCE OF COVARIATES: APPLICATION TO ALCOHOLISM RESEARCH. Alcohol and Alcoholism, 2005, 40, 124-131.	1.6	4
51	Therapeutic Monitoring of Aripiprazole by HPLC with Column-Switching and Spectrophotometric Detection. Clinical Chemistry, 2005, 51, 1718-1721.	3.2	67
52	Validating the DemTect with 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography as a Sensitive Neuropsychological Screening Test for Early Alzheimer Disease in Patients of a Memory Clinic. Dementia and Geriatric Cognitive Disorders, 2005, 20, 271-277.	1,5	32
53	Functional implications of hippocampal volume and diffusivity in mild cognitive impairment. NeuroImage, 2005, 28, 1033-1042.	4.2	181
54	Color-coded diffusion-tensor-imaging of posterior cingulate fiber tracts in mild cognitive impairment. Neurobiology of Aging, 2005, 26, 1193-1198.	3.1	253

Matthias J. Müller

#	Article	IF	CITATIONS
55	Association of elevated phospho-tau levels with alzheimer-typical 18F-Fluoro-2-Deoxy-D-Glucose positron emission tomography findings in patients with mild cognitive impairment. Biological Psychiatry, 2004, 56, 279-283.	1.3	45
56	Ultrastructural Hippocampal and White Matter Alterations in Mild Cognitive Impairment: A Diffusion Tensor Imaging Study. Dementia and Geriatric Cognitive Disorders, 2004, 18, 101-108.	1.5	272
57	Heart rate variability during sleep in patients with schizophrenia treated with olanzapine. International Clinical Psychopharmacology, 2004, 19, 325-330.	1.7	12
58	Therapeutic Monitoring of New Antipsychotic Drugs. Therapeutic Drug Monitoring, 2004, 26, 156-160.	2.0	105
59	Combination Treatment With Nefazodone and Cognitive-Behavioral Therapy for Relapse Prevention in Alcohol-Dependent Men. Journal of Clinical Psychiatry, 2004, 65, 1406-1413.	2.2	29
60	Standardized rater training for the Hamilton Depression Rating Scale (HAMD-17) in psychiatric novices. Journal of Affective Disorders, 2003, 77, 65-69.	4.1	62
61	Differentiating moderate and severe depression using the Montgomery–Åsberg depression rating scale (MADRS). Journal of Affective Disorders, 2003, 77, 255-260.	4.1	210
62	Distigmine bromide induced acute psychotic disorder in a patient with multiple sclerosis. European Psychiatry, 2003, 18, 318-319.	0.2	7
63	Symptom-Triggered versus Standard Chlormethiazole Treatment of Inpatient Alcohol Withdrawal: Clinical Implications from a Chart Analysis. European Addiction Research, 2003, 9, 1-7.	2.4	32
64	Subchronic Haloperidol Downregulates Dopamine Synthesis Capacity in the Brain of Schizophrenic Patients In Vivo. Neuropsychopharmacology, 2003, 28, 787-794.	5.4	105
65	Early Improvement Under Mirtazapine and Paroxetine Predicts Later Stable Response and Remission With High Sensitivity in Patients With Major Depression. Journal of Clinical Psychiatry, 2003, 64, 413-420.	2.2	160
66	Effects of Interrater Reliability of Psychopathologic Assessment on Power and Sample Size Calculations in Clinical Trials. Journal of Clinical Psychopharmacology, 2002, 22, 318-325.	1.4	52
67	Dose-Related Effects of Amisulpride on Five Dimensions of Psychopathology in Patients With Acute Exacerbation of Schizophrenia. Journal of Clinical Psychopharmacology, 2002, 22, 554-560.	1.4	26
68	Overlap between emotional blunting, depression, and extrapyramidal symptoms in schizophrenia. Schizophrenia Research, 2002, 57, 307-309.	2.0	15
69	Syndrome profiles in alcoholism and panic disorder with or without agoraphobia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 1079-1087.	4.8	7
70	Frequency and dependence on body posture of hallucinations and sleep paralysis in a community sample. Journal of Sleep Research, 2002, 11, 179-180.	3.2	21
71	Patients' satisfaction with psychiatric treatment: comparison between an open and a closed ward. Psychiatric Quarterly, 2002, 73, 93-107.	2.1	36
72	Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients. Schizophrenia Research, 2001, 49, 223-225.	2.0	38

Matthias J. Müller

#	Article	IF	CITATIONS
73	No Association Between the Dopamine D2 Receptor Taq I A1 Allele and Earlier Age of Onset of Alcohol Dependence According to Different Specified Criteria. Alcoholism: Clinical and Experimental Research, 2001, 25, 805-809.	2.4	23
74	Mortality in affective disorders. Journal of Affective Disorders, 2001, 65, 263-274.	4.1	35
75	Lower self-reported depression in patients with erectile dysfunction after treatment with sildenafil. Journal of Affective Disorders, 2001, 66, 255-261.	4.1	30
76	Moderate and severe depression. Journal of Affective Disorders, 2000, 60, 137-140.	4.1	97
77	Carbohydrate-Deficient Transferrin (CDT) and HDL Cholesterol (HDL) Are Highly Correlated in Male Alcohol Dependent Patients. Alcoholism: Clinical and Experimental Research, 2000, 24, 497-500.	2.4	1
78	Occupancy of striatal D 2 -like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic. Psychopharmacology, 1999, 146, 81-86.	3.1	19
79	The Calgary Depression Rating Scale for Schizophrenia: development and interrater reliability of a German version (CDSS-G). Journal of Psychiatric Research, 1999, 33, 433-443.	3.1	69
80	Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial. Psychiatry Research, 1999, 89, 275-280.	3.3	19
81	Three dimensions of depression in patients with acute psychotic disorders: A replication study. Comprehensive Psychiatry, 1999, 40, 449-457.	3.1	12
82	Relationship of Psychiatric Experience and Interrater Reliability in Assessment of Negative Symptoms. Journal of Nervous and Mental Disease, 1999, 187, 316-318.	1.0	9
83	Dimensionality of depression in acute schizophrenia: a methodological study using the Bech-Rafaelsen Melancholia Scale (BRMES). Journal of Psychiatric Research, 1998, 32, 369-378.	3.1	29
84	Evaluation of standardized rater training for the Positive and Negative Syndrome Scale (PANSS). Schizophrenia Research, 1998, 32, 151-160.	2.0	46
85	Risperidone Versus Haloperidol and Amitriptyline in the Treatment of Patients With a Combined Psychotic and Depressive Syndrome. Journal of Clinical Psychopharmacology, 1998, 18, 111-120.	1.4	93
86	Effect of sleep deprivation on neuroendocrine response to a serotonergic probe in healthy male subjects. Journal of Psychiatric Research, 1997, 31, 543-554.	3.1	15
87	Side effects of adjunct light therapy in patients with major depression. European Archives of Psychiatry and Clinical Neuroscience, 1997, 247, 252-258.	3.2	17
88	Catecholamine Response Curves of Male Hypertensives Identified by Lehmacher's Two Sample Configural Frequency Analysis. Biometrical Journal, 1997, 39, 29-38.	1.0	6
89	Revisiting the Ehlers and Kupfer hypothesis: The growth hormone cortisol secretion ratio during sleep is correlated with electroencephalographic slow wave activity in normal volunteers. Biological Psychiatry, 1996, 39, 139-142.	1.3	18
90	Human plasma DSIP decreases at the initiation of sleep at different circadian times. Peptides, 1995, 16, 1475-1481.	2.4	10

#	Article	IF	CITATIONS
91	Serial partial sleep deprivation as adjuvant treatment of depressive insomnia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1995, 19, 593-602.	4.8	16
92	Salivary Testosterone and Simple Reaction Time Parameters. Neuropsychobiology, 1994, 30, 173-177.	1.9	11